American Journal of Respiratory and Critical Care Medicine | 2019
Sleep Apnea Heterogeneity, Phenotypes, and Cardiovascular Risk. Implications for Trial Design and Precision Sleep Medicine
Abstract
et al. Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection. J Infect Dis 2017;216:1398–1406. 10. DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 2015;373:2048–2058. 11. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014;371:711–722. 12. World Health Organization. Human challenge trials for vaccine development: regulatory considerations. Presented at the Expert Committee on Biological Standardization. October 17–21, 2016, Geneva, Switzerland, pp. 1–12. 13. European Medicines Agency, Evaluation of Medicines for Human Use. Committee for Human Medicinal Products (CHMP) note for guidance on the clinical evaluation of vaccines. 2005 [accessed 2019 Jan 28]. Available from: https:// www.dcvmn.org/IMG/pdf/emea_note_guidanceclinical_ evaluation_vaccines.pdf.